Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death|
|Citation:||Journal of Antimicrobial Chemotherapy, 2010; 65(5):1042-1051|
|Publisher:||Oxford Univ Press|
|Monica A. Slavin, Tania C. Sorrell, Deborah Marriott, Karin A. Thursky, Quoc Nguyen, David H. Ellis, C. Orla Morrissey, Sharon C.-A. Chen and on behalf of the Australian Candidemia Study, Australasian Society for Infectious Diseases.(Group, Collaboration)|
|Abstract:||Background Candidaemia in cancer patients is associated with increasing fluconazole resistance. Models for predicting such isolates and their clinical impact are required. Methods Clinical, treatment and outcome data from a population-based candidaemia survey (2001–2004) were collected at 5 and 30 days after diagnosis. Speciation and antifungal susceptibility testing was performed. Results There were 138 candidaemia episodes (33% Candida albicans) in adults with haematological malignancies and 150 (51% C. albicans) in adults with solid organ malignancies. Thirty-nine isolates had fluconazole MICs of ≥64 mg/L and 40 had MICs of 16–32 mg/L (predominantly Candida glabrata and Candida krusei). By multivariate analysis, triazole therapy, gastrointestinal tract (GIT) surgery in the 30 days before candidaemia and age >65 years were predictive of fluconazole-resistant candidaemia. Thirty day crude mortality was 40% in haematology patients and 45% in oncology patients. Fluconazole-resistant isolates were associated with increased risk of mortality by univariate (P = 0.04) and Kaplan–Meier survival analyses. By Cox proportional hazards modelling, the strongest predictors of mortality at onset of candidaemia were invasive ventilation, elevated creatinine, intensive care unit (ICU) admission and receipt of systemic triazoles or corticosteroids in the previous 30 days. Removal of a central venous access device (CVAD) at or within 5 days of onset was associated with decreased mortality. Conclusions Risk factors for fluconazole-resistant candidaemia in adults with cancer include fluconazole/triazole exposure and GIT surgery. ICU admission, invasive ventilation, renal impairment, age >65 years and prior exposure to corticosteroids and triazoles are risk factors for death. CVAD removal reduced mortality. These findings should be integrated into surveillance and treatment algorithms.|
|Keywords:||mortality; Candida; triazoles; susceptibility|
|Rights:||© The Author 2010.Copyright© 2011 British Society for Antimicrobial Chemotherapy|
|Appears in Collections:||Molecular and Biomedical Science publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.